ClinicalTrials.gg
TerminatedNCT02739360Updated Mar 4, 2020Results posted

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

A Phase 4 interventional study of Idelalisib in Lymphoid Malignancies, sponsored by Gilead Sciences. Terminated at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.

02

Conditions studied

  • Lymphoid Malignancies
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Receiving GS-9820 in Study GS-US-315-0102 with objective evidence of clinical benefit
  • Evidence of a personally signed

Key Exclusion Criteria:

  • Known or intolerance to any of the active substances or in the formulation of idelalisib
  • Toxicities that would preclude initiating therapy with idelalisib prior to enrollment
  • Concurrent participation in another therapeutic clinical trial
  • Ongoing infection, treatment, or prophylaxis for cytomegalovirus (CMV) within the past 28 days.

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Idelalisib

    Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.

    Drug: Idelalisib

Interventions

  • Idelalisib 150 mg tablet administered orally twice daily

    Also known as: Zydelig®

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths

    The severity of Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. An SAE was defined as an event that, at any dose, resulted in one or more of the following: 1) Death, 2) Life-threatening, 3) In-patient hospitalization or prolongation of existing hospitalization, 4) Persistent or significant disability/incapacity, 5) A congenital anomaly/birth defect, or 6) A medically important event or reaction.

    Time frame: Up to Day 602 plus 30 days

07

Results

Posted Jan 16, 2019

Participant flow

Participants were enrolled at study sites in the Netherlands. The first participant was screened on 04 May 2016. The last study visit occurred on 28 December 2017.

Participant flow — Overall Study
MilestoneIdelalisib
Started3
Completed0
Not completed3
Withdrew: Adverse event1
Withdrew: Study terminated by sponsor2

Outcome measures

PrimaryNumber of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths

The severity of Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. An SAE was defined as an event that, at any dose, resulted in one or more of the following: 1) Death, 2) Life-threatening, 3) In-patient hospitalization or prolongation of existing hospitalization, 4) Persistent or significant disability/incapacity, 5) A congenital anomaly/birth defect, or 6) A medically important event or reaction.

Time frame:
Up to Day 602 plus 30 days
Reported as:
Number · Participants
Number of Participants Experiencing Treatment-Emergent ≥ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths
ParticipantsIdelalisib
≥ Grade 3 Adverse Event1
SAE1
Death0

Adverse events

Collected over Up to Day 602 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Idelalisib0/3 (0%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventIdelalisib
CholangitisHepatobiliary disorders1/3
Lung disorderRespiratory, thoracic and mediastinal disorders1/3
Most frequent other events
Showing 10 of 22
Most frequent other events
EventIdelalisib
Urinary tract infectionInfections and infestations3/3
AnaemiaBlood and lymphatic system disorders1/3
Vision blurredEye disorders1/3
Abdominal distensionGastrointestinal disorders1/3
ConstipationGastrointestinal disorders1/3
DiarrhoeaGastrointestinal disorders1/3
Dry mouthGastrointestinal disorders1/3
NauseaGastrointestinal disorders1/3
FatigueGeneral disorders1/3
Influenza like illnessGeneral disorders1/3

Baseline characteristics

Safety Analysis Set: participants who took at least 1 dose of study drug.

Age, Customized
Age, Customized(Participants)Idelalisib
From 65 - 84 years3
Sex: Female, Male
Sex: Female, Male(Participants)Idelalisib
Female2
Male1
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Idelalisib
08

Study locations

1 site
  • Amsterdam, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Dec 2017, 19 months.

Results were first posted in Jan 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2016
First posted
Apr 15, 2016
StartActual
May 4, 2016
Primary completionActual
Dec 28, 2017
CompletionActual
Dec 28, 2017
Results first posted
Jan 16, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02739360
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 15, 2016
Start date
May 4, 2016
Primary completion
Dec 28, 2017
Completion
Dec 28, 2017
Results posted
Jan 16, 2019
Last update
Mar 4, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Idelalisib

Start the discussion